



# Resource impact template

Resource impact

Published: 11 December 2024

Last updated: 11 December 2024

[www.nice.org.uk](http://www.nice.org.uk)

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for relapsed and refractory multiple myeloma after 3 or more treatments:

- [Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments](#) (2025) NICE technology appraisal guidance 1114
- [Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments](#) (2024) NICE technology appraisal guidance 1023
- [Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments](#) (2024) NICE technology appraisal guidance 1015
- [Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments](#) (2024) NICE technology appraisal guidance 970